scholarly journals Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis

2017 ◽  
Vol 23 (11) ◽  
pp. 1298-1308 ◽  
Author(s):  
Cen Xie ◽  
Tomoki Yagai ◽  
Yuhong Luo ◽  
Xianyi Liang ◽  
Tao Chen ◽  
...  
2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Emma Barroso ◽  
Rosalía Rodríguez-Rodríguez ◽  
Mohammad Zarei ◽  
Javier Pizarro-Degado ◽  
Anna Planavila ◽  
...  

Abstract Background Deficiency of mitochondrial sirtuin 3 (SIRT3), a NAD+-dependent protein deacetylase that maintains redox status and lipid homeostasis, contributes to hepatic steatosis. In this study, we investigated additional mechanisms that might play a role in aggravating hepatic steatosis in Sirt3-deficient mice fed a high-fat diet (HFD). Methods Studies were conducted in wild-type (WT) and Sirt3−/− mice fed a standard diet or a HFD and in SIRT3-knockdown human Huh-7 hepatoma cells. Results Sirt3−/− mice fed a HFD presented exacerbated hepatic steatosis that was accompanied by decreased expression and DNA-binding activity of peroxisome proliferator-activated receptor (PPAR) α and of several of its target genes involved in fatty acid oxidation, compared to WT mice fed the HFD. Interestingly, Sirt3 deficiency in liver and its knockdown in Huh-7 cells resulted in upregulation of the nuclear levels of LIPIN1, a PPARα co-activator, and of the protein that controls its levels and localization, hypoxia-inducible factor 1α (HIF-1α). These changes were prevented by lipid exposure through a mechanism that might involve a decrease in succinate levels. Finally, Sirt3−/− mice fed the HFD showed increased levels of some proteins involved in lipid uptake, such as CD36 and the VLDL receptor. The upregulation in CD36 was confirmed in Huh-7 cells treated with a SIRT3 inhibitor or transfected with SIRT3 siRNA and incubated with palmitate, an effect that was prevented by the Nrf2 inhibitor ML385. Conclusion These findings demonstrate new mechanisms by which Sirt3 deficiency contributes to hepatic steatosis. Graphical abstract


2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Amandine Thomas ◽  
Elise Belaidi ◽  
Judith Aron-Wisnewsky ◽  
Gerard C. van der Zon ◽  
Patrick Levy ◽  
...  

2009 ◽  
Vol 136 (2) ◽  
pp. 607-618 ◽  
Author(s):  
Julio C. Morote–Garcia ◽  
Peter Rosenberger ◽  
Nicole M.I. Nivillac ◽  
Imogen R. Coe ◽  
Holger K. Eltzschig

2018 ◽  
Vol 285 ◽  
pp. 14-20 ◽  
Author(s):  
Huanhuan Jin ◽  
Naqi Lian ◽  
Mianli Bian ◽  
Chenxi Zhang ◽  
Xingran Chen ◽  
...  

2020 ◽  
Vol 246 (1) ◽  
pp. 57-67 ◽  
Author(s):  
Lei Yu ◽  
Haoran Wang ◽  
Xiaoxue Han ◽  
Honghui Liu ◽  
Dalong Zhu ◽  
...  

Non-alcoholic fatty liver disease (NAFLD) is difficult to manage due to the lack of effective treatments. Increased oxygen consumption caused by overnutrition, along with reduced oxygen delivery to liver cells induces hepatic steatosis. Here, we investigated the efficacy of oxygen therapy (OT) to alleviate hepatic steatosis. The effect of OT on hepatic steatosis was evaluated in high-fat-diet (HFD)-fed mice and palmitic acid (PA)-treated primary hepatocytes. Liver biopsy tissue samples were used to determine the relationship between the expression of hypoxia-inducible factor-2α (HIF-2α) and the progression of NAFLD. The role of HIF-2α in the OT group was determined based on the overexpression of HIF-2α in vitro. OT safely alleviated hepatic hypoxia and improved hepatic steatosis by inhibiting hepatic de novo lipogenesis in HFD-fed mice and PA-treated primary hepatocytes, and this was accompanied by reduced expression of HIF-2α and hepatic de novo lipogenesis. The analysis of liver tissues from individuals with or without NAFLD revealed a positive correlation between hepatic HIF-2α expression and NAFLD progression. Overexpression of HIF-2α in vitro inhibited the beneficial effect of OT against hepatic lipogenesis and steatosis. OT might be a viable treatment option for NAFLD and functions by alleviating hypoxia and inhibiting the liver HIF-2α signaling pathway.


Sign in / Sign up

Export Citation Format

Share Document